ILMN stock is taking a major hit in Friday’s trading session after the DNA sequencing company Illumina, Inc. (NASDAQ:ILMN) stated that its Q2 2019 revenue will miss projections because of challenges with its direct-to-consumer genomic initiatives as well as weakening sales of the sequencing systems. The company also slashed its full-year top-line guidance.
Illumina to Miss Q2 2019 by $50 MillionIn its projections, the company indicated that it will post Q2 2019 revenue of around $835 million relative to the $830 million that was posted in the same quarter a year ago. Although that will ...
Read The Full Article On StreetSignals.com
Get the latest stock market news on StreetSignals. Follow public companies and get free stock research reports and stock market analysis data and stock tips.
All content provided by StreetSignals is subject to our Terms Of Use and Disclaimer.